📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
1 articles
AVG GRADE
HIGH
score: 1.00
SENTIMENT
BULLISH
TOTAL VIEWS
7
RECENT COVERAGE · 5 ARTICLES
Zymeworks to pay $17/share for Theravance Biopharma in $929M deal
ZymeworksTheravance Biopharma at $17 per share represents a consolidation move within the biopharmaceutical sector. The $929 million...
Zymeworks To Acquire Theravance Biopharma For $929 Mln In Cash Deal, TBPH Stock Down In Pre-Market
Zymeworks announced an acquisition of Theravance Biopharma for $929 million in an all-cash transaction at $17.00 per share. This...
Zymeworks to Acquire Theravance Biopharma, Inc.
Zymeworks announced an acquisition of Theravance Biopharma at $17 per share, representing a significant M&A event in the...
Zymeworks to Acquire Theravance Biopharma, Inc.
Zymeworks (ZYME) announced a definitive acquisition of Theravance Biopharma (TBPH), combining two established biotech players in a...
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
Zymeworks (ZYME) released Phase 1 data for ZW191, a folate receptor alpha-targeting antibody-drug conjugate (ADC), demonstrating...
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice